gRNA Market Size, Share & Trends Analysis Report By Product & Services (Products, Custom gRNA Synthesis Services), By gRNA Type (Research-Use), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

gRNA Market Size & Trends

The global gRNA market size was estimated at USD 497.9 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2030. gRNA is in high demand due to its pivotal role in CRISPR-based genetic editing. Its unique ability to guide the CRISPR system to specific DNA sequences makes it an indispensable tool in precision gene editing. Researchers and scientists rely on gRNA to precisely target and modify genes, enabling groundbreaking advancements in medicine, agriculture, & biotechnology. Its versatility, accuracy, and efficiency have propelled its demand, promising potential cures for genetic disorders, innovative agricultural practices, and the study of fundamental biological processes. As the quest for targeted genetic modifications intensifies, gRNA remains a sought-after component driving genetic research.

gRNA technology has shown potential in both areas, leading to the development of rapid CRISPR-based COVID-19 tests and research into CRISPR-based antiviral therapies. The pandemic increased public awareness and interest in gene-editing technologies such as CRISPR-Cas9, leading to greater recognition of gRNA's potential and driving market awareness. COVID-19 highlighted the importance of personalized medicine, as individuals responded differently to the virus.

The expanding R&D activities in proteomics and genomics are significant factors driving the market. R&D efforts in genomics aim to identify and validate potential therapeutic targets and understand the functions of genes. gRNAs play a crucial role in this process by enabling precise gene editing using CRISPR/Cas systems. Researchers use gRNAs to modify genes of interest and study their effects, facilitating the identification and validation of key targets. Proteomics and genomics R&D often involve large-scale studies to uncover the functions of genes and proteins. gRNAs are instrumental in functional genomics research, allowing researchers to knock out or modulate specific genes selectively. This capability aids in understanding gene function and unraveling complex biological pathways.

Governments and private organizations are investing heavily in proteomics and genomics research, leading to a surge in demand for gRNA technology. For instance, in April 2021, the U.S. government announced USD 1.7 billion in funding to support and expand genomic sequencing technologies.

Market Concentration & Characteristics

Product & Services Insights

Product segment accounted for the largest revenue share of 73.4% in 2023. These products offer high accuracy, efficiency, and specificity in gene editing, making them popular among researchers. In addition to products, the market also offers numerous services, such as gRNA design, synthesis, and delivery. These services enable researchers to customize their gene editing experiments with tailor-made gRNA sequences and delivery systems. This helps achieve better accuracy and specificity in gene editing experiments. Furthermore, the widescale availability and high purity of these products is the major reason for the segment’s dominance.

Custom gRNA synthesis services segment is estimated to register the fastest CAGR over the forecast period. These services are offered by biotechnology companies specializing in gene editing technologies and provide a range of options for researchers to design & order custom gRNAs that meet their specific experimental needs. Thus, propelling the segment growth.

gRNA Type Insights

The research-use segment dominated the market share in 2023. A large number of research programs conducted across various research institutes demand research-grade gRNA. With increasing applications of gRNA in clinical research, the segment is expected to maintain its dominance over the forecast period. Moreover, the growing adoption of CRISPR/Cas9 technology, a widely used gene-editing tool, is further driving the demand for gRNA in the research-use segment.

GMP-grade segment is estimated to register the fastest CAGR over the forecast period. This segment focuses on the production of gRNA under strict quality control and regulatory guidelines for use in clinical trials & patient treatment. Enforcing GMP ensures that the products are manufactured consistently and controlled, with high levels of quality assurance. This is especially important for applications in the medical field, where safety and efficacy are of utmost importance. The availability of GMP-grade gRNA products is expected to drive the gene editing market, particularly in personalized medicine.

Application Insights

The genome engineering segment dominated the global market share in 2023 and has been anticipated to grow at the fastest CAGR during the forecast period. Genome engineering is a lucrative application for gRNA due to its transformative impact across diverse industries. The precision and versatility of gRNA within CRISPR-based editing have revolutionized genetic modifications, presenting immense opportunities in medicine, agriculture, & biotechnology.

Genome engineering with gRNA plays a pivotal role in synthetic biology, allowing the design and construction of artificial biological systems. This is particularly valuable in industrial biotechnology for optimizing microbial strains for the production of biofuels, pharmaceuticals, and other bioproducts and hence, increase the demand for genome engineering and further boost the market growth.

End-use Insights

The pharmaceutical & biotechnology companies segment dominated the global market share in 2023. The adoption of gRNA in precision medicine by pharmaceutical and biotech companies fuels its market growth as it becomes integral to the development of personalized therapies. Biotechnology companies use gRNA for optimizing bioproduction processes, such as the development of cell lines for biotherapeutic production. The integration of gRNA in bioproduction applications contributes to process efficiency, reducing production timelines and costs.

Academic research institutes segment is estimated to register the fastest CAGR over the forecast period. Academic researchers use gRNA to investigate gene functions, study biological mechanisms, and make fundamental discoveries in molecular biology. The constant demand for advanced tools like gRNA in academic research fosters market growth as researchers seek innovative solutions for their studies. Thus, boosting the market growth.

Regional Insights

North America dominated the overall global market in 2023 with a revenue share of 52.6%. Factors such as the local presence of a substantial number of key players such as Thermo Fisher Scientific; Merck KGaA.; among others, coupled with an upsurge in research and development spending by key players to develop innovative and advanced products are attributed for the gRNA industry growth in the region.For instance, in May 2023, Thermo Fisher Scientific, Inc. and Pfizer, Inc. collaborated to expand access to NGS-based testing for cancer patients. The initial focus of the partnership is on lung and breast cancer, two of the most common and deadly cancers worldwide. This is expected to lead to an increased demand for gRNAs targeting genes associated with these specific cancers.

U.S. accounted for the largest share of the global market in North America in 2023. The market in the U.S. has witnessed notable growth, driven by advancements in gene-editing technologies and their applications across various industries. As a crucial component of CRISPR-based systems, gRNA has found diverse applications in research, diagnostics, and potentially therapeutic interventions. This is expected to support growth over the forecast period.

Asia Pacific region is expected to grow at the fastest CAGR during the forecast period. Factors such as the presence of a significant target population, faster adoption of an array of technologies, several startups coupled with developing healthcare infrastructure, and the existence of high-unmet clinical needs are anticipated to provide growth opportunities to key manufacturers in the region.

The market in China is rapidly growing due to the increasing demand for genome editing technologies. The country has become one of the leading players in the global biotech industry and has invested heavily in R&D of gRNA-based products. The Chinese government has also implemented several policies to encourage the development of the biotech industry, including tax incentives, funding for R&D, and simplified regulatory procedures. This has attracted many domestic and foreign companies to invest in the market in China.

Key Companies & Market Share Insights

Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies Inc. are some of the dominant players operating in gRNA market.

• Thermo Fisher Scientific, Inc. has a global presence and operates from over 65 locations in North America, Europe, Asia Pacific and other regions.

• Agilent Technologies, Inc. is a global company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories.

Jena Bioscience GmbH, System Biosciences, LLC.Synbio Technologies and others are some of the emerging market players functioning in the market.

• System Biosciences Company intended to provide comprehensive research for the discovery, isolation, and characterization of exosomes.

• Synbio Technologies offerings include antibody services, synthetic biology solutions, DNA editing, DNA reading, DNA/RNA writing, and protein & peptide services.

Recent Developments

• In May 2023, Revvity Inc (Horizon Discovery Ltd.), a life sciences and diagnostic business of PerkinElmer, Inc. acquired Horizon Discovery Ltd. Furthermore, in May 2023, PerkinElmer’s life sciences and diagnostics arm rebranded as Revvity.

• In July 2022, Synthego launched a 20,000-square-foot manufacturing facility designed to deliver GMP single guide RNA (sgRNA) at scale.

• In October 2021, Merck KGaA signed an agreement to license its patented CRISPR-Cas9 technology to Cellecta, Inc., the U.S. based afunctional genomics products and services provider.

gRNA Market Report Scope

Global gRNA Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the gRNA market report based on product & services, gRNA type, application, end-use, and region:

• Product & Services Outlook (Revenue, USD Million, 2018 - 2030)

  • Products

    • gRNA Final Products

    • gRNA Synthesis Products

      • gRNA Synthesis Kits

      • Plasmids

      • Others

  • Custom gRNA Synthesis Services

• gRNA Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Research-Use

  • GMP-grade

• Application Outlook (Revenue, USD Million; 2018 - 2030)

  • Genome Engineering

  • Disease Model Studies

  • Functional Genomics

  • Epigenetics

  • Others

• End-use Outlook (Revenue, USD Million; 2018 - 2030)

  • Pharmaceutical & Biotechnology Companies

  • Academic Research Institutes

  • CMOs & CROs

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait